Second-generation antipsychotics for obsessive compulsive disorder.

@article{Komossa2010SecondgenerationAF,
  title={Second-generation antipsychotics for obsessive compulsive disorder.},
  author={Katja Komossa and Anna M Depping and Magdalena Meyer and Werner Kissling and Stefan Leucht},
  journal={The Cochrane database of systematic reviews},
  year={2010},
  volume={12},
  pages={
          CD008141
        }
}
BACKGROUND Obsessive compulsive disorder (OCD) is a psychiatric disorder which has been shown to affect 2 to 3.5% of people during their lifetimes. Inadequate response occurs in 40% to 60% of people that are prescribed first line pharmaceutical treatments (selective serotonin reuptake inhibitors (SSRIs)). To date not much is known about the efficacy and adverse effects of second-generation antipsychotic drugs (SGAs) in people suffering from OCD. OBJECTIVES To evaluate the effects of SGAs… 

Figures from this paper

Treatment-Resistant Obsessive-Compulsive Disorder (OCD): Focus on Antipsychotic Augmentation to SRIs
TLDR
Risperidone and aripiprazole can be considered as the agents of first choice and should be preferred to the others antipsychotic in SRI-resistant-OCD and olanzapine may be a valid alternative to ris peridone.
TREATMENT-RESISTANT OBSESSIVE-COMPULSIVE DISORDER ( OCD ) : CURRENT KNOWLEDGE AND OPEN QUESTIONS
TLDR
Several evidence-based effective strategies are available to clinicians in case of treatment-resistant OCD and a treatment algorithm for those patients who fail to respond to a first SRI trial is built.
Atypical antipsychotic augmentation in SSRI treatment refractory obsessive-compulsive disorder: a systematic review and meta-analysis
TLDR
Risperidone and aripiprazole can be used cautiously at a low dose as an augmentation agent in non-responders to SSRIs and CBT but should be monitored at 4 weeks to determine efficacy.
Antipsychotics in treatment-resistant Obsessive-Compulsive Disorder : which antipsychotic , which dose and how long antipsychotic addition should be maintained
TLDR
Not all antipsychotics are effective as add-on treatments in resistant OCD, and preliminary results from open label studies suggest that antipsychotic augmentation, once effective, should be maintained in order to maintain remission.
Second Generation Antipsychotic-Induced Obsessive-Compulsive Symptoms in Schizophrenia: A Review of the Experimental Literature
TLDR
It is suggested that clozapine confers the greatest risk of OCS in schizophrenia, with 20 to 28 % of clozAPine-treated patients experiencing de novo OCS, in addition to 10 to 18 % incurring an exacerbation of pre-existing OCS.
Critical Review of the Use of Second-Generation Antipsychotics in Obsessive–Compulsive and Related Disorders
TLDR
This review sought to examine all the published reports of second-generation antipsychotics being used in the management of symptoms of the aforementioned diseases and compile evidence for clinicians who encounter patients who are unresponsive to standard treatment.
Augmentation strategies in obsessive–compulsive disorder
TLDR
The available evidence for augmentation strategies is predominantly based on small-scale, randomized controlled trials, open-label trials and case series, and antipsychotic augmentation, especially risperidone, haloperidol, aripiprazole and cognitive-behavior therapy have shown the best evidence.
Pharmacological treatment strategies in obsessive compulsive disorder: A cross-sectional view in nine international OCD centers
TLDR
Results from this international cross-sectional study indicate that current OCD treatment is in line with evidence-based treatment guidelines, and no significant differences in OCD symptom severity were found between monotherapy and augmentation or between different therapeutic agents.
...
...

References

SHOWING 1-10 OF 65 REFERENCES
Risperidone and haloperidol augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder: a crossover study.
TLDR
Adjunctive risperidone improved obsessions and depressed mood and was well tolerated in patients with SRI-refractory OCD.
Risperidone augmentation of serotonin reuptake inhibitors in obsessive-compulsive and related disorders.
TLDR
Patients with OCD and related disorders are not infrequently refractory to treatment with serotonin reuptake inhibitors and controlled trials of risperidone augmentation in such patients seem warranted, it is necessary to determine an appropriate dose range to minimize adverse effects.
Olanzapine augmentation for treatment-resistant obsessive-compulsive disorder.
TLDR
Improvement in OCD was independent of improvement in mood symptoms and double-blind, placebo-controlled trials are warranted along with trials comparing risperidone and olanzapine augmentation.
Augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder using adjunctive olanzapine: a placebo-controlled trial.
TLDR
Preliminary evidence is provided that adding olanzapine to SRIs is potentially efficacious and well tolerated in the short-term treatment of patients with refractory OCD.
Quetiapine Addition to Serotonin Reuptake Inhibitors in Patients With Severe Obsessive-Compulsive Disorder: A Double-Blind, Randomized, Placebo-Controlled Study
TLDR
In this study, augmentation of SRI treatment with quetiapine in severe OCD had no additional effect and the total Yale-Brown Obsessive-Compulsive Scale score was the primary efficacy parameter.
Quetiapine augmentation of serotonin reuptake inhibitors in obsessive-compulsive disorder
TLDR
Although limited by the retrospective design and lack of controls, these data are consistent with the growing literature suggesting that approximately one-half of OCD patients resistant to treatment with SRIs may respond to augmentation with an atypical antipsychotic.
Quetiapine augmentation in patients with treatment resistant obsessive–compulsive disorder: a single-blind, placebo-controlled study
TLDR
The addition of quetiapine to ongoing SRI therapy has been found to be effective and well-tolerated approach in patients with refractory OCD.
A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder.
TLDR
It is suggested that OCD patients with and without comorbid chronic tic disorders or schizotypal personality disorder may respond to the addition of low-dose risperidone to ongoing SRI therapy.
Pharmacotherapy augmentation strategies in treatment-resistant anxiety disorders.
TLDR
Medication augmentation can be an effective and well-tolerated short-term treatment strategy for non-responders to first-line pharmacotherapy of anxiety disorders, but any conclusions must be tentative in view of methodological and clinical heterogeneity.
...
...